Teaching and Research Section of Neurology, Xuzhou Medical College, Xuzhou, 221002, China.
Cell Biochem Biophys. 2014 May;69(1):179-87. doi: 10.1007/s12013-013-9756-8.
Currently, autologous bone marrow-derived stem cell is one of the most innovative areas of stem cells research. Previous studies on animal models of nervous system diseases have shown that these cells have a good effect on nervous system disorders. The alternative treatment with stem cells for the nervous system diseases has also gradually reached to clinical application stage. The prospect is captivating, but the safety and efficacy of this procedure need further research. To observe the clinical efficacy and side effects of the treatment for autologous mesenchymal stem cells and neural stem/progenitor cells which are in differentiated form by inducing with cerebrospinal fluid in the patients with nervous system diseases, thirty patients were selected from our hospital (2009-10 to 2012-07) and were followed at 1 month, 3 months, 6 months, 1 year and 2 years after the treatment with autologous mesenchymal stem cells and neural stem/progenitor cells in differentiated form was introduced. In this paper, we will introduce the process to make cells accessible for the clinical application by the description of the changes observed in 7 cases were followed for 2 years. The time for bone marrow mesenchymal stem cells could be available for clinical needs is as early as 5 days, not later than 10 days, and the median time is 8 days, while neural stem/progenitor cells in differentiated form can be available for clinical needs in as early as 12 days, not later than 15 days, and the median time is 13.5 days (statistical explanation: Case 5 only uses autologous mesenchymal stem cells, and Case 7 has two times bone marrow punctures). The neurological function of the patients was improved in 1-month follow-up, and the patients have a better discontinuous trend (statistical explanation: sometimes the neurological function of the patients between two adjacent follow-ups does not change significantly). After transplantation, four patients appeared to have transient fever, but it was easily controlled by symptomatic treatment. Seven patients did not appear to show secondary tumor induced by transplantation of stem cells in 2-year follow-up. Thus, it suggests that the use of autologous bone marrow-derived stem cells transplantation in patients with nervous system diseases is a feasible, convenient, safe, and effective method.
目前，自体骨髓源性干细胞是干细胞研究中最具创新性的领域之一。先前在神经系统疾病动物模型上的研究表明，这些细胞对神经系统紊乱有很好的疗效。用干细胞对神经系统疾病进行替代治疗也逐渐进入临床应用阶段。前景令人着迷，但该程序的安全性和有效性需要进一步研究。为了观察诱导性分化的自体间充质干细胞和神经干细胞/祖细胞治疗神经系统疾病的临床疗效和副作用，我们从我院选择了 30 例患者（2009-10 至 2012-07），在引入诱导性分化的自体间充质干细胞和神经干细胞/祖细胞治疗后，分别于 1 个月、3 个月、6 个月、1 年和 2 年进行随访。本文将通过对 7 例随访 2 年的病例变化描述，介绍将细胞应用于临床的过程。骨髓间充质干细胞可用于临床需求的时间最早为 5 天，最晚为 10 天，中位数时间为 8 天，而诱导性分化的神经干细胞/祖细胞可用于临床需求的时间最早为 12 天，最晚为 15 天，中位数时间为 13.5 天（统计学解释：病例 5 仅使用自体间充质干细胞，病例 7 进行了两次骨髓穿刺）。在 1 个月的随访中，患者的神经功能得到改善，且患者呈较好的间断趋势（统计学解释：有时患者在两次相邻随访之间的神经功能变化不明显）。移植后，有 4 例患者出现一过性发热，但通过对症治疗容易控制。在 2 年的随访中，7 例患者未出现移植后干细胞诱导的继发性肿瘤。因此，提示自体骨髓源性干细胞移植治疗神经系统疾病是一种可行、方便、安全、有效的方法。
